s of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.
FOR INFORMATION CONTACT:Elisha Finney (650) 424-6803
elisha.finney@varian.com
Spencer Sias (650) 424-5782
spencer.sias@varian.com
A summary of earnings and other financial information follows.Varian Medical Systems, Inc. and Subsidiaries Condensed Consolidated Statements of Earnings
(Unaudited)(Dollars and shares in millions, except per share amounts)Q4 QTR2012Q4 QTR2011Q4 YTD2012Q4 YTD2011Net orders
$
963.6967.93,121.92,933.5 Oncology Systems788.6717.22,400.12,249.5 X-Ray Products145.3126.3505.6482.8 Security & Inspection Products29.035.889.9109.9 Varian Particle Therapy 0.788.6125.790.9Ginzton Technology Center--0.60.4Order backlog$
2,844.32,529.52,844.32,529.5Revenues
$
756.1719.02,807.02,596.7 Oncology Systems590.1549.12,189.52,021.9 X-Ray Products130.1119.0492.6469.2 Other35.950.9124.9105.6Cost of revenues
$
432.9418.71,610.71,460.8Gross margin323.2300.31,196.31,135.9 As a percent of revenues42.8%41.8%42.6%43.7%Operating expenses Research and development 45.943.9185.7170.7 Selling, general and administrative 109.596.7416.5376.8O
'/>"/>
SOURCE Varian Medical Systems Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine technology :1.
Varian Medical Systems Signs Purchase Agreement with Advanced Particle Therapy LLC to Supply Technology for the Georgia Proton Treatment Center to be operated by Emory Healthcare2.
Varian Medical Systems Publishes 2012 Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements3.
Institut Curie Acquires Four Advanced Radiotherapy Treatment Systems Including Three Varian TrueBeam Devices4.
Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer5.
Varian Medical Systems Establishes Subsidiary in South Korea6.
Cancer Patients in Central Vietnam to Gain Access to Advanced Radiotherapy Treatments Using Technology from Varian Medical Systems7.
Varian Medical Systems to Support an NCI-Sponsored Phase III Study Comparing Radiosurgery with Surgery for the Treatment of Early-Stage High-Risk, Operable Non-Small Cell Lung Cancer8.
Erich R. Reinhardt Appointed to Board of Directors of Varian Medical Systems9.
Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock through Calendar Year 201310.
Varian Medical Systems CEO Timothy E. Guertin Announces Plans to Retire; Board of Directors Names Dow R. Wilson as Successor11.
Researchers Discover All-Natural Weapon In The War Against Ovarian Cancer